Tag: Japanese Pharma

Eisai Launched Equfina® in Japan

Eisai Co., Ltd. announced that it has launched the Equfina® 50mg TABLETS (safinamide mesilate, “Equfina”) for the indication of improvement of wearing-off phenomenon in patients with Parkinson’s disea...

Lupin Discussing Sale of Kyowa Pharmaceuticals for $600m

India’s Lupin Ltd is in advanced talks to sell its Japanese generics subsidiary Kyowa Pharmaceuticals for an enterprise value of $600 million to a local player as it steps up efforts to significantly ...

Shionogi & Co. Announced License Agreement with Hsiri Therapeutics

japan
Shionogi & Co., Ltd. announced that it has entered into a new license agreement with Hsiri Therapeutics, Inc. regarding a collaborative research and development program to discover and develop add...

Daiichi Sankyo Announced Launch of VANFLYTA® in Japan

Daiichi Sankyo Company, Limited announced the launch of VANFLYTA® (quizartinib), an oral FLT3 inhibitor, in Japan for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid le...

Eisai and Meiji Seika Announced Manufacturing and Marketing Approval in Japan for Equfina® TABLETS

japan
Eisai Co., Ltd. and Meiji Seika Pharma Co., Ltd. announced the manufacturing and marketing approval in Japan for the indication of improvement of wearing-off phenomenon in patients with Parkinson’s di...

Velabs and Chiome to Discover Modulatory and functional Antibodies

Velabs Therapeutics, specializing in the fast generation of functional therapeutic antibodies, announced that its cooperation with Chiome Bioscience, Inc., Tokyo, will be deepened, to jointly discover...

FDA Approved New Parkinson’s Disease Treatment

Kyowa Kirin Co., Ltd., announces today that the U.S. Food and Drug Administration (FDA) has granted approval for NOURIANZTM (istradefylline) for use as adjunctive treatment to levodopa/carbidopa in ad...

FUJIFILM Irvine Scientific Opens Facility in Netherlands

FUJIFILM Irvine Scientific, Inc., a global leader in the innovation, development, and manufacture of cell culture media, announced plans to open a third manufacturing facility located in Tilburg, Neth...

Novartis’ Cancer Treatment Kymriah Approved for Sale in Japan

A Japanese government panel approved on Wednesday a price of 33.5 million yen ($305,800) for Novartis’ cancer treatment Kymriah, allowing the Swiss drugmaker to press ahead with a campaign to kick-sta...

Exscientia Establishes Subsidiary for Expanding in Asia

Exscientia, the world-leading Artificial Intelligence (AI)-driven drug discovery company announces the establishment of a subsidiary, Exscientia K.K to spearhead its pharmaceutical interests across As...

Blackstone Acquires Japanese Company

Blackstone announced that private equity funds managed by Blackstone have entered into a definitive agreement to acquire AYUMI Pharmaceutical Corporation (“AYUMI” or “the Company”), a leading specialt...

AGC Aquires Spanish Synthetic API Manufacturing Plant

AGC (Headquarters: Tokyo; President: Takuya Shimamura) announces the completion of its acquisition of the synthetic pharmaceutical active ingredient manufacturing plant, Malgrat Pharma Chemicals, S.L....

FDA Approval for Taiho Oncology

Taiho Oncology, Inc. today announced that the United States Food and Drug Administration (FDA) has approved LONSURF® as a treatment for adult patients with metastatic gastric or gastroesophageal junct...

Use of iPSC for Spinal Cord Injures Will Be Tested in Japan

Japanese scientists will test the use of human-induced pluripotent stem cells (iPS) to treat spinal cord injuries, a health ministry panel that approved the research project said on Monday. The res...

First Drug for Rare Cancer under Priority Review

Daiichi Sankyo has been given a priority review from the FDA for pexidartinib, which is vying to become the first systemic drug therapy for rare cancer tenosynovial giant cell tumour (TGCT). The Ja...

Latuda’s Positive Results for Patients with Schizophrenia

Japan-based Sumitomo Dainippon Pharma has published positive results from the phase III JEWEL trial into its drug Latuda (lurasidone hydrochloride) for patients with schizophrenia. The JEWEL study ...